Search
Our new and improved patient folder is a comprehensive resource to help families navigate a new type 1 diabetes diagnosis, now and into the future.
Discover essential insights on food and nutrition for Type 1 Diabetes, from carb counting to meal planning.
Pump Comparison tool . This easy-to-use updated comparison tool is designed to help you pick the right device for your family.
Websites we think you'll find useful.
Find out how to participate in our research and community groups.
We are in a new era of T1D care. We can now identify and provide care for people across a spectrum of T1D, from early-stage T1D to symptomatic insulin requiring T1D (Stage 3 and Stage 4). And for the first time since the discovery of insulin over 100 years ago, Australia has approved a new therapy, Teplizumab.
T1D can be a traumatic diagnosis for children and young people, and often involves strict adherence to painful treatments, comorbid mental health conditions, and shortened life expectancy.
The DiabHQ Patient Portal app is now available to WA children and families living with Type 1 diabetes.
Hybrid closed-loop (HCL) therapy is an efficacious management strategy for young people with type 1 diabetes. However, high costs prevent equitable access. We thus sought to evaluate the cost-effectiveness of HCL therapy compared with current care among young people with type 1 diabetes in Australia.
The Environmental Determinants of Islet Autoimmunity (ENDIA) study is an Australia-wide pregnancy-birth cohort study following children who have a first-degree relative with type 1 diabetes (ACTRN1261300794707). A dedicated ENDIA Facebook page was established in 2013 with the aim of enhancing recruitment and supporting participant retention through dissemination of study information.